A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.
about
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateSteroid avoidance or withdrawal for kidney transplant recipients.Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials.Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi.A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimusDesign and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant p
P2860
Q28067598-0A06F44C-1B5C-43ED-89ED-D9DAC3FBC6D9Q30248364-C0770420-4B46-4119-BAFE-55330C41858DQ31138722-54ED883D-80D0-4B4F-AB9C-B1465F123640Q36255504-0613FDC6-60B9-4800-B5B8-CDD29D33ACEDQ38229930-4350069A-EC27-4EA9-9D9E-45F289736DD5Q38668601-E4FEC70E-C37D-45DC-9ACD-10CFFF71D48BQ38779769-27733124-2931-4946-97C2-9F01E9A755C9Q40176051-CB8AA962-D950-4230-B512-A3609320A22AQ40856064-9B41487D-2138-422D-BE1C-B7F871241B92Q47812723-3FCE7B69-B4AC-470F-B559-E6A5FB059AF5Q48140331-483E1112-A740-4EA0-A9E9-07A7A3CBC7BFQ53633264-D5258583-9879-4019-AEC2-E1C5A5267E7BQ56035477-1B726F0A-4D67-42BA-990E-2155CE4AA9B3Q56970934-D2CE6039-BA82-4C6C-86DF-E3483CC25A6C
P2860
A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A randomized, controlled trial ...... kidney transplant recipients.
@ast
A randomized, controlled trial ...... kidney transplant recipients.
@en
A randomized, controlled trial ...... kidney transplant recipients.
@nl
type
label
A randomized, controlled trial ...... kidney transplant recipients.
@ast
A randomized, controlled trial ...... kidney transplant recipients.
@en
A randomized, controlled trial ...... kidney transplant recipients.
@nl
prefLabel
A randomized, controlled trial ...... kidney transplant recipients.
@ast
A randomized, controlled trial ...... kidney transplant recipients.
@en
A randomized, controlled trial ...... kidney transplant recipients.
@nl
P2093
P2860
P356
P1476
A randomized, controlled trial ...... kidney transplant recipients.
@en
P2093
Chad Woodcock
Graeme Russ
Helen Pilmore
John Kanellis
Josette Marie Eris
Nicol Kurstjens
Po Chang Lee
SOCRATES Study Group
Steven J Chadban
P2860
P304
P356
10.1111/TRI.12252
P50
P577
2014-01-06T00:00:00Z